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Abstract        
        
For a primary active pump like the human ATP-Binding-Cassette (ABC) transporter 
ABCB1, coupling of drug-binding by the two transmembrane domains (TMDs) to the 
ATP catalytic cycle of the two nucleotide-binding domains (NBDs) is fundamental to the 
transport mechanism but is poorly understood at the biochemical level. Structure data 
suggest that signals are transduced through intracellular loops of the TMDs that slot into 
grooves on the NBDs. At the base of these grooves is the Q-loop. We therefore mutated 
the eponymous glutamine in one or both NBD Q-loops and measured the impact on 
conformation and function using a conformation-sensitive antibody and fluorescent 
drugs, respectively. We show that the double mutant is trapped in the inward-open state 
which binds drug but cannot couple to the ATPase cycle. Our data also describe 
remarkable redundancy within the transport mechanism because single Q-loop mutants 
are functional for Bodipy-verapamil transport. This allowed us to elucidate transduction 
pathways from twin drug-binding cavities to the Q-loops using point mutations to favour 
one cavity over the other. Together, the data show that the Q-loop is the central flexion 





ABC transporter molecular mechanism 












The human ATP Binding Cassette (ABC) transporter ABCB1, formerly known as P-
glycoprotein and MDR1, is an efflux pump of very broad solute specificity that includes 
lipid-signalling molecules and drugs of therapeutic value. Its function is known to cause 
clinical multidrug resistance (1). ABCB1 is a prototypical ABC transporter consisting of four 
domains in a single polypeptide (2): two nucleotide-binding domains (NBDs) form two 
composite ATP-binding pockets, and two transmembrane domains (TMDs) form the 
translocation pathway across the lipid bilayer and impart specificity by binding the 
transported drugs (3-5).  
 
X-ray structure models of five homologous ABC exporters are present in the protein 
database (drug efflux pumps from Mus musculus (Abcb1a) (6), Staphylococcus aureus 
(Sav1866) (7) and Caenorhabditis elegans (CeAbcb1) (8); the lipid A exporter from various 
Gram negative bacteria (9); and a mitochondrial transporter of unknown function (ABCB10) 
from Homo sapiens (10)). The apo forms of four of these, Abcb1a, CeAbcb1, MsbA from 
Vibrio cholera and ABCB10 crystallized in an inward-open conformation in which there is 
no direct intramolecular contact between the two NBDs (depicted in the left hand model of 
Figure 1A). Their TMD α-helices are angled such that they describe an inverted ‘V’, 
forming an apex at the extracellular face of the membrane. The large internal cavity, open 
towards the inner leaflet of the membrane and the cytosol, is thought to form the solute-
binding surface (Abcb1a was also co-crystallized with cyclic peptide inhibitors bound in this 
cavity). The resolution of the Abcb1a structure does not allow precise assignment of the 
amino acids involved in co-ordinating the bound drugs, but pharmacological labelling and 
modelling studies demonstrate the presence of two cavities at the TMD:TMD interface 
which are related by two-fold pseudo-symmetry and which can be separated by mutation 
(11-13). Both cavities are capable of binding verapamil, and the bundles of α-helices formed 
by the TMDs as they cross the membrane ensures that amino acid residues from both TMDs 
line each cavity (Figure 1B) (12). In contrast, MsbA from Salmonella typhimurium and 
Sav1866 were crystallized in an inward-closed conformation (depicted in the central and 
right hand models of Figure 1A). The NBDs of these transporters are in close apposition and 
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co-ordinate nucleotide or nucleotide analogues at their interface. In this inward-closed 
conformation the TMD α-helices describe a regular ‘V’ that exposes the putative solute 
binding sites extracellularly. Co-crystals of ABCB10 with nucleotide analogues were also 
obtained. These holo structures crystallised both in an inward-open state and in various 
partially-closed states suggesting that nucleotide by itself is insufficient to trigger formation 
of an inward-closed conformation for ABCB10 that is stable under crystallization conditions. 
 
Taken together, the structure data suggest a bellows-like mechanism (Figure 1A) that 
conforms to the alternate access mode of action of membrane pumps first proposed by 
Jardetzky in 1966 (14). For ABCB1, drugs are reported to bind to the TMDs directly from 
the inner leaflet of the membrane. These would need to induce conformational change at the 
NBDs which allows the NBDs to interact directly and bind two molecules of ATP at their 
interface (the structure data for ABCB10 suggests that the NBDs may be poised with ATP 
already bound to the F1-core subdomains (see below) in the absence of drug). In ABCB1, 
nucleotide binding is reported to be sufficient to lower the affinity for drug and presumably 
also reconfigures the drug-binding cavities to release drug extracellularly (15, 16). The 
energy released from subsequent ATP hydrolysis is thought to be used to drive the exporter 
back to the inward-open conformation to re-expose the binding cavities to the inner leaflet of 
the membrane and restore their high affinity for drugs. This coupling of the aspect and 
affinity of the drug-binding sites of the TMDs to the closure of the NBD:NBD interface 
around the bound ATPs is fundamental to the transport cycle of ABC exporters but is poorly 
understood at the molecular mechanistic level. It is to the nature of the TMD:NBD interface 
that we need to look to understand it. The ABC exporter structure data (modelled for 
ABCB1 in Figures 1C and 1D) shows that the conserved Q-loop occupies a position at the 
base of a cleft in the top surface of the NBD into which a short helix formed by the TMD is 
docked. Each TMD of ABC exporters forms two such helices at the apices of two long 
intracellular loops. These two helices contact different NBDs allowing both TMDs to 
influence both NBDs even when the two NBDs are spatially separated. The TMDs of type I 
and type II ABC importers, epitomised by the maltose importer MalEFGK2 (17) and the 
vitamin B12 importer BtuC2D2 (18), respectively, form only one “coupling” helix which, 
despite the lack of primary sequence similarity, is structurally and positionally equivalent to 
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the ABC exporter helix that fits into the cleft lined by the Q-loop (19-21). The Q-loop also 
links the F1-core and α-helical subdomains of the NBDs (best illustrated in Figure 3). In the 
inward-closed conformation of the ABC exporters, the two ATPs are bound between the F1-
core of one NBD and the α-helical subdomain of the second (Figure 1D). Higher resolution 
structural data obtained for soluble bacterial NBDs crystallized in the presence and absence 
of nucleotides suggested that flexion of the Q-loop may allow movement of the α-helical 
subdomain with respect to the F1-core to control allosteric coupling between the two ATP-
binding pockets (22-24). The Q-loop is therefore critically positioned to couple ligand 
binding by the TMDs to ATP binding at the NBDs in all ABC transporters.  
 
We report here the first evidence of the crucial role played by the Q-loops in the 
intramolecular coupling mechanism of human ABCB1. Our approach was to mutate the 
eponymous glutamine in one, or both, NBD Q-loops and measure the impact on ABCB1 
conformation and function. By combining these Q-loop mutants with further mutations in the 
TMDs that prevent occupancy of one or other drug-binding cavity we have also dissected the 
energy transduction pathways coupling the individual drug-binding cavities to the ATP 
catalytic cycle of the transporter. 
 
Materials and Methods 
 
Reagents. Dulbecco’s modified eagle medium (DMEM), DMEM/F-12, fetal bovine 
serum (FBS), phosphate buffered saline (PBS), TrypLE Express, and Bodipy-verapamil 
were all purchased from Invitrogen (Carlsbad, CA). The detergent n-dodecyl-β-D-
maltoside was purchased from Merck Serono (Feltham, UK). Lipids were purchased from 
Avanti Polar Lipids (Alabaster, AL). All other general chemicals were from Sigma 
(Poole, UK). 
 
Plasmids. Mutations were introduced into a plasmid encoding human ABCB1 with a C-
terminal hexahistidine tag (pCIneo-wtABCB1-6His; described previously (25)) by site-
directed mutagenesis (QuikChange XL; Stratagene, La Jolla, CA) using the following 
oligonucleotides:  
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Q132A, 5’-GGTTGCTGCTTACATCGCGGTTTCATTTTGGTGC-3’;  
Q132R, 5’-GGTTGCTGCTTACATTCGAGTTTCATTTTGGTGC-3’; 
Q475A, 5’-GGGAAATCATTGGTGTGGTGAGTGCTGAGCCTGTATTGTTTGCCACCACG-3’;  
Q773A, 5’-GGAATTATTTCTTTTATTACATTTTTCCTTGCGGGTTTCACATTTGGCAAAGCTGG-3’;  
Q773R, 5’-GGAATTATTTCTTTTATTACATTTTTCCTTCGAGGTTTCACATTTGGCAAAGCTGG-3’;  
Q1118A, 5’-GGGCATCGTGTCCGCGGAACCCATCCTGTTTG-3’;  
E556Q, 5’-CCCCAAGATCCTCCTGCTTGATCAGGCCACGTCAGCCTTGG-3’; 
E1201Q, 5’-CAGCCTCATATTTTGCTTCTTGATCAGGCCACGTCAGCTCTGGATAC-3’.  
For expression in insect cells, the tagged wild-type and mutant ABCB1 cDNAs were sub-
cloned into the baculovirus transfer vector pBlueBAC4.5 (Invitrogen, Carlsbad, CA) 
using BamHI and NotI restriction sites at the 5’- and 3’-ends of the gene, respectively. 
The veracity of all plasmids was confirmed by DNA sequencing.  
 
Expression in human cells. HEK293T cells were transfected-transiently using 
polyethyleneimine (PEI), as described previously (25). Equivalent expression levels of 
each mutant ABCB1 and wild-type protein were confirmed using saturating amounts of 
the ABCB1-specific primary antibody 4E3 (AbD Serotec, Oxford, UK) and R-
phycoerythrin-conjugated goat anti-mouse secondary antibodies (Dako UK Ltd, Ely, 
UK), as described previously (26). UIC2-PE binding was carried out as described by the 
supplier (Immunotech, Beckman Coulter, CZ). 
 
Drug transport assays. Each ABCB1 mutant was assessed for function using the 
fluorescent drug accumulation assay, described previously (25, 27). Briefly, HEK293T 
cells were transfected transiently with plasmids encoding wild-type or mutant ABCB1 
and harvested 48 hours post-transfection. The live cells were incubated with 4E3 
antibody, as described above, to label the surface ABCB1, and then with Bodipy-
verapamil (0.8 μM) for 30min at 37oC to assess transport activity. The fluorescence 
associated with cells of normal size and granularity was quantified using a FACScan flow 
cytometer. Flow cytometry data were acquired using CellQuest (BD Biosciences, San 
Jose, CA) and analysed using FlowJo (Tree Star, Ashland, OR). As each population of 
transfected cells contains both transfected (ABCB1-expressing) and untransfected 
(ABCB1-negative) cells distinguished on the basis of 4E3 antibody binding, the 
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untransfected subpopulation was used as an internal control for measuring Bodipy-
verapamil accumulation. ABCB1 transport activity was assessed as the fold difference in 
drug accumulation between the ABCB1-expressing and non-expressing cell populations 
within each experiment.  
 
Confocal microscopy. Primary antibody 4E3 (AbD Serotec, Oxford, UK) was 
conjugated to Alexa633 dye using the Mix-n-Stain (Biotium, Hayward, CA, USA) 
according to the manufacturer’s instructions. Transiently-transfected HEK293T cells 
were split, 24h post-transfection, onto glass-chamber slides (Lab-Tek, Thermo Fisher 
Scientific, Waltham, Massachusetts, USA). 48hrs post-transfection, the live cells were 
washed 3x in DMEM/F12 medium then incubated with the Alexa633-conjugated 4E3 
antibody (1/100 dilution in DMEM/F12 medium) plus Bodipy-verapamil (0.8μM) for 
30min at 37oC, 5% CO2. The cells were washed 3x then imaged using a Zeiss LSM510 
inverted confocal laser scanning microscope. Images were obtained using a plan-
apochromat 63x oil objective with a numerical aperture of 1.4. Bodipy was excited using 
the Argon laser (488nm laser line) and Alexa633 using the HeNe laser (633nm). Bodipy 
emission was detected using the HFT UV/488/543/633 main dichroic beam splitter in 
combination with a band pass filter (BP 505-530) and Alexa633 was detected using a 
NFT 545 secondary beam splitter and a long pass filter (LP650). Multitrack mode 
allowed for crosstalk-free imaging of the two dyes. 
 
Purification of ABCB1. Generation of recombinant baculovirus, growth and 
maintenance of High Five insect cells and the production of crude membrane fractions 
was as described elsewhere (28). ABCB1 was purified from crude membrane fractions 
using Ni-NTA resin (Qiagen) as described previously (29), with the following 
modifications. Initial binding of solubilised membrane protein to the resin was performed 
in the presence of 5mM imidazole; wash steps used 20mM, 30mM and 35mM imidazole. 
Purified protein was eluted from the resin in 120mM imidazole. To monitor purification, 
proteins were separated by 7.5% SDS-PAGE and visualized by colloidal blue staining.  
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Reconstitution of purified ABCB1 into proteoliposomes and measurement of 
ATPase activity. ABCB1 was reconstituted into liposomes as described previously (29). 
To assess efficiency, the lipid was spiked with [3H]-phosphatidylcholine and lipid and 
protein were equilibrated in a sucrose gradient by ultracentrifugation. Protein and lipid 
content of the fractions were analysed by SDS-PAGE and liquid scintillation counting, 
respectively, as detailed elsewhere (28).                                 
 
Cytosensor microphysiometer measurements of extracellular acidification rates 
(ECAR). ECAR of live HEK293T cells were measured in an eight-channel Cytosensor 
microphysiometer (Molecular Devices, Menlo Park, CA), as described elsewhere (31-34). 
Briefly, 6 x 105 cells were seeded onto 12mm diameter polycarbonate cell capsule cups in 
1ml cell culture medium and incubated for 6h at 37oC. On transfer to the Cytosensor, the 
culture medium was replaced by pumping low buffer-capacity flow medium (prepared 
from dry powder DMEM without sodium bicarbonate, but supplemented with 1mM 
sodium pyruvate to reduce basal ECAR values, and 2.6 g/L sodium chloride to preserve 
osmolarity) through the flow chamber at a rate of 100μl/min. The cells were left to 
equilibrate until a constant ECAR was reached (30-60 minutes) before switching the 
medium flowing over the cells to drug-containing medium. A measuring cycle lasted 2 
minutes during which the flow was switched off for 20 seconds to measure acidification 
yielding one data point. Each stimulation cycle for a given drug concentration was 
repeated several times, after which the cells were washed with pure medium until the 
basal activity was recovered. All stimulations were reversible. Cells are primarily 
glycolytic in culture, hence, one molecule of glucose consumed is converted into two 
molecules of ATP and two molecules of lactic acid. The latter are secreted from the cell 
and quantified via ECAR measurements. As ATP is resynthesized on demand, the 
number of lactic acid molecules extruded directly corresponds to the number of ATP 
molecules consumed.  
ECAR data were analysed using a two-site binding model based on uncompetitive 
inhibition, described previously (31, 35-37), in which drug activates ABCB1 at low 




Vs, ECAR as a function of the drug concentration Cs; V0, basal ECAR in the absence of 
drug; V1, maximum ECAR assuming only activation; V2, activity at infinite drug 
concentration; K1, drug concentration giving half-maximum activation; K2, drug 
concentration giving half-maximum reduction. 
 
Statistical analyses. Student’s two-tailed t-test was used to analyse differences between 
means. Differences among means were analysed using two-way ANOVA followed by 




The Q-loops of the NBDs are essential for drug efflux but redundancy is built into 
the molecular mechanism. Site-directed mutagenesis was used to introduce glutamine-
to-alanine mutations into NBD1 (NBD1-Q475A), NBD2 (NBD2-Q1118A), and into both 
NBDs of human ABCB1. As controls, mutations E556Q and E1201Q in the Walker B 
motifs of each NBD that render the transporter catalytically-inactive were also generated. 
HEK293T cells were transfected transiently with each of the plasmids and the expression 
and function of the mutant and wild-type transporters was analysed by two-wavelength 
flow cytometry. The non-inhibitory anti-ABCB1 antibody (4E3) which recognises an 
extracellular loop of the transporter was used at saturating concentrations with a red 
fluorescent secondary to determine the level of expression at the plasma membrane, and 
the green fluorescent drug derivative (Bodipy-verapamil) was used to assess transport 
activity. Figure 2A shows a representative dotplot for a population of cells transfected 
with pCIneo-wtABCB1-6His showing that cells expressing ABCB1 (upper left 
population) accumulate very little Bodipy-verapamil compared with non-transfected cells 
(lower right population) within the same sample. The fold difference in drug 
accumulation between the G1 and G2 gated cells provides a measure of the transport 















effect on the level of protein expression in HEK293T cells as shown in the example 
histogram describing 4E3 staining (Figure 2B). Cell populations with equal surface 
expression of mutant and wild-type forms of ABCB1 could therefore be gated for analysis 
of transport function (analytical gates G1 and G2 in Figure 2, correspond to regions M1 
and M2 in Figure 2B, respectively). Cells expressing the single NBD Q-loop mutants, 
NBD1-Q475A, or NBD2-Q1118A, accumulated only low levels of Bodipy-verapamil 
similar, but not identical to, those expressing wild-type ABCB1 (Figure 2C). The 
reproducible but subtle difference in Bodipy-verapamil transport activity by the single Q-
loop mutants did not reach statistical significance (shown in the first four columns of 
Figure 6). In contrast, cells expressing the double mutant Q475A/Q1118A exhibited no 
efflux activity, and rather surprisingly, and reproducibly, accumulated more Bodipy-
verapamil than mock-transfected cells or cells expressing the Walker B mutant E1201Q of 
ABCB1 (Figure 2C; the raw dotplot data also showed that Bodipy-verapamil accumulation 
increases linearly with increasing expression of Q475A/Q1118A (Supplementary Figure 
1)).  
 
The double Q-loop Q475A/Q1118A mutant is trapped in the inward-open 
conformation. The extracellular loops of human ABCB1 form a discontinuous epitope for 
the antibody UIC2, characterised by Igor Roninson’s group (38, 39). UIC2 is sensitive to 
the conformation of ABCB1 and binds preferentially to ATP-free ABCB1, corresponding 
to the inward-open conformation shown in Figure 1A. Consequently, UIC2 binds more 
readily to wild-type ABCB1 than the Walker B mutant E1201Q (Figure 2D) in cells that 
express equal amounts of these proteins, because the Walker B mutant can bind but cannot 
hydrolyse ATP (40). The Walker B mutants therefore get trapped in the inward-closed 
conformation with a stable NBD:NBD interface around the bound ATP. UIC2 
reproducibly binds most readily to the Q475A/Q1118A mutant suggesting that it adopts a 
conformation consistent with the inward-open state that would be expected to have a high 
affinity for UIC2. The single Q-loop mutants exhibit a phenotype for UIC2 binding that is 
indistinguishable from the wild-type transporter, reflecting the levels of functionality of 




The additional Bodipy-verapamil accumulated by cells that express the double Q-loop 
mutant prompted examination of the subcellular localisation of the accumulated drug. 
Confocal microscopy showed that cells expressing wild-type ABCB1 (stained with the 
non-inhibitory 4E3 conjugated to a red-fluorophore) accumulated no fluorescent drug 
(Figure 3, upper panels) because the wild-type transporter efficiently effluxes drug from 
the cells. Non-expressing cells included in the same field of view accumulated the green 
Bodipy-verapamil in intracellular compartments. In contrast, cells expressing the 
Q475A/Q1118A mutant accumulated Bodipy-verapamil both in intracellular 
compartments and the plasma membrane where it co-localises with the 4E3 staining 
(Figure 3, middle panels). Prior data shows that in the absence of ATP, ABCB1 adopts a 
conformation with a high affinity for drug (16). The microscopy data is therefore 
consistent with the UIC2-binding data and suggests that the Q475A/Q1118A adopts the 
inward-open conformation which, in the absence of the two Q-loop glutamines cannot 
form the NBD:NBD interface, provides additional drug-binding sites in the plasma 
membrane, and explains the increased accumulation of Bodipy-verapamil in these cells. 
In contrast, no Bodipy-verapamil was detected bound to the Walker B E1201Q mutant 
which becomes trapped in the inward-closed conformation. Cells expressing this mutant 
therefore accumulate drug only intracellularly (Figure 3, lower panels). This is also 
consistent with previously published data which shows that non-hydrolysable 
trinucleotides trap ABCB1 in a conformation with a low affinity for drug (16).  
 
The single Q-loop mutants retain the ability to hydrolyse ATP in live cells but not 
post-purification. The drug export activity of the single Q-loop mutants was unexpected 
because equivalent mutations in mouse Abcb1a were reported to reduce drug-stimulated 
ATPase activity by >95% (41). In this earlier paper, the activity of the purified protein 
was characterised thoroughly in vitro, but drug transport was not analysed. Our 
observations of the human transporter, interpreted in light of this prior data, suggested 
that drug transport may have become uncoupled from ATPase activity in ABCB1. We 
therefore replicated the Abcb1a experiments performed previously, with the human 
transporter. Wild-type and mutant forms of the human transporter were expressed in 
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insect cells, solubilised from the membrane using n-dodecyl-β-D-maltoside  (DDM), and 
purified by nickel-affinity chromatography (Figure 4A). ABCB1 is inactive in DDM at 
the concentrations needed for solubilisation therefore the purified protein was mixed with 
detergent-solubilised membrane lipids and ABCB1-liposomes were reconstituted by the 
slow removal of detergent.  
 
The kinetics of drug-stimulated ATPase activity of wild-type and mutant ABCB1 fitted 
the Michaelis-Menten equation (Figure 4B). The low basal ATPase activity of the wild-
type ABCB1 that was stimulated 11-fold by drug to a high Vmax for ATP hydrolysis of 1.7 
μmol/min/mg and a Km of 0.75mM (Table 1) compared favourably with previous reports 
of the catalytic activity of purified ABCB1, indicative of efficient reconstitution of the 
active transporter into proteoliposomes (42-44). The drug-stimulated ATPase activity of 
the single Q-loop mutants was reduced to 9.5% and 8.1% of the wild-type activity for the 
NBD1-Q475A and NBD2-Q1118A mutants, respectively, and the double mutant was 
inactive (the basal ATPase activities of these mutants were similarly affected; Figure 4B 
and C). The observed difference was not due to the differential ability of the mutant 
proteins to form proteoliposomes as all three mutants reconstituted into the lipid with the 
same efficiency as the wild-type protein (Supplementary Figure 2). The data are largely 
consistent with the in vitro observations of Urbatsch et al., (41), effectively ruling out the 
possibility that the Q-loop mutants of mouse Abcb1a and human ABCB1 differ 
significantly.  
 
These in vitro data suggested uncoupling of drug transport from ATPase activity in the 
single Q-loop mutants. However, to prove this unequivocally would require measurement 
of ATPase activity and drug transport in the same system. ABCB1 drug transport into 
proteoliposomes does not appear to be possible, most likely due to low protein:lipid 
ratios, the hydrophobicity, and the leakiness of large unilamellar liposomes to the 
transported drugs, so we therefore measured the ATPase activity of ABCB1 in intact 
human cells using extracellular acidification rates (ECAR) as a proxy. ECAR is non-
invasive and measures the increase in lactate efflux from the cell which directly correlates 
to turnover of ATP upon drug stimulation in living cells (Figure 5A-E). The data best 
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fitted a modified Michaelis-Menten equation producing bell-shaped curves, consistent 
with previous work which showed that a variety of different drugs stimulate ABCB1 at 
low concentrations but inhibit the transporter at high concentrations (31, 45).  
 
Cells expressing wild-type ABCB1 exhibited a drug-stimulated acidification rate (V1 
value) 1.34-fold above basal, whereas mock transfected cells had a negligible response 
(<1.05-fold), indicating that the increase in ECAR was due to the expression, and ATP 
catalytic activity, of ABCB1 (Table 2). The V1 values for cells expressing single mutants 
NBD1-Q475A and NBD2-Q1118A were 1.19-fold and 1.13-fold above basal rates, 
respectively, corresponding to 50% and 35% of the ATPase activity of wild-type 
ABCB1. No increase in ECAR in the presence of verapamil was detected in cells 
expressing the Q-loop double mutant Q475A/Q1118A. It seems likely therefore, that the 
lack of correlation with the in vitro data is due to inactivation of the single Q-loop 
mutants during purification. The simplest conclusion is that 9 out of every 10 transporter 
proteins reconstituted into proteoliposome preparations of single Q-loop mutants are 
inactive thus accounting for the reduction in both basal and drug-stimulated ATPase 
activity in these preparations. Together, these data show that the very low ATPase 
activity in vitro described in Table 1 and reported previously is an artefact due to the 
instability of the Q-loop mutants during purification. 
 
The Q-loops are necessary to couple the drug-binding sites to the ATP binding sites. 
The two pseudo-symmetrical drug-binding cavities of ABCB1 can be manipulated 
independently by mutagenesis of residues Q132 (TMD1) and Q773 (TMD2) that line the 
cavities (Figure 1B, (12)). Replacement of the two TMD glutamines with arginines is 
reported to repel positively-charged drugs but have no effect on neutral drugs. Single 
mutants in which the glutamine in either TMD1 or TMD2 was replaced with arginine had 
intermediate phenotypes consistent with transport of the positively-charged drug only 
from the remaining wild-type drug-binding cavity (12). We introduced these glutamine to 
arginine mutations into ABCB1 and assessed their effect on Bodipy-verapamil export 
using two-colour flow cytometry. The TMD mutations had no effect on ABCB1 
expression at the plasma membrane (Supplementary Figure 3). The single mutant TMD1-
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Q132R was able to efflux Bodipy-verapamil with 70% efficiency of the wild-type protein 
while the TMD2-Q773R was fully active and indistinguishable from wild-type ABCB1 
(grey bars in Figure 6 in which transport data are presented as the fold reduction in 
Bodipy-verapamil accumulation compared to mock-transfected cells). These data are 
consistent with prior observations which concluded that verapamil had a preference for 
binding to the cavity lined by Q132 (12). The double arginine mutant Q132R/Q773R, 
retains ability to export Bodipy-verapamil but it is significantly reduced to 42% 
(p<0.001) of wild-type ABCB1 activity. This residual activity is likely due to the partial 
masking of the positive charge on verapamil by the Bodipy moiety such that electrostatic 
repulsion from Q132R or Q773R is incomplete. The catalytically-inactive Walker B 
mutants NBD1-E556Q and NBD2-E1201Q (46) were also tested for comparison and are 
unable to efflux Bodipy-verapamil. 
 
To test whether each verapamil-binding cavity was coupled to the NBDs via a specific Q-
loop we combined the single drug-cavity mutants TMD1-Q132R and TMD2-Q773R with 
the NBD Q-loop mutants NBD1-Q475A and NBD2-Q1118A and compared their 
transport activity (striped bars in Figure 6) with that of the drug cavity mutants and also 
the single and double Q-loop mutants (white bars; note that the double Q-loop mutant has 
a fold-difference that is less than 1 because it provides additional binding sites for 
Bodipy-verapamil in the membrane). The drug-cavity mutant TMD1-Q132R combined 
synergistically with NBD1-Q475A to significantly reduce Bodipy-verapamil export 
activity to 25% of wild-type activity, but in combination with NBD2-Q1118A the 
transporter retained the full level of activity of each single mutant (at 85% of the wild-
type activity this was not significantly different from the Q132R mutant or the Q1118A 
mutant). This shows that the wild-type Q773-lined verapamil-binding cavity of the 
Q132R mutant is dedicated to, and only requires, the NBD1 Q-loop to couple to the ATP 
catalytic cycle. In contrast, TMD2-Q773R combined synergistically with both NBD1-
Q475A and NBD2-Q1118A to reduce Bodipy-verapamil export activity to 22% and 34% 
of the wild-type activity, respectively. This shows that the wild-type Q132-lined 
verapamil-binding cavity of these mutants is coupled to, and requires, the Q-loops of both 





The Q-loop is the flexion point where the aspect and affinity of the drug-binding 
cavities couple to the ATP catalytic cycle.  
The Q-loops are essential to the molecular mechanism of ABCB1, because the double Q-
loop mutant is trapped in an inward-open conformation that retains affinity for Bodipy-
verapamil but cannot trigger the transport cycle and therefore cannot efflux Bodipy-
verapamil. In contrast, the single Q-loop mutants retain wild-type levels of Bodipy-
verapamil transport activity, demonstrating a surprising level of redundancy in the 
mechanism that is not observed for Walker B mutants of ABC exporters ((47) and data 
herein) or in ABC importers (48). The high level of Bodipy-verapamil efflux activity of 
the single Q-loop mutants in live cells allowed the role of the Q-loop in the coupling 
mechanism of ABCB1 to be investigated. The single Q-loop mutants combined with 
TMD mutants, Q132R in TMD1 or Q773R in TMD2, which line the two verapamil-
binding cavities (12), showed that Bodipy-verapamil bound to the cavity lined by TMD2-
Q773 triggers conformation change to the inward-closed state via the conduit of the Q-
loop in NBD1. In reciprocal experiments, in which the transporter preferentially engaged 
drug via the Q132-lined cavity (by introduction of the Q773R mutation) both Q-loops 
were required to efficiently couple efflux of the bound Bodipy-verapamil to the ATP 
catalytic cycle. Together, these data place the Q-loops at the centre of the molecular 
mechanism where they control the coupling of the alternate access cycle of the TMDs 
with the ATP catalytic cycle of the NBDs. 
 
We envisage the role of the Q-loop in the transport cycle of an ABC exporter as follows. 
The drug-binding cavities of ABCB1 in the inward-open state are exposed to the inner 
leaflet of the membrane and its NBDs are completely separated as observed in crystals of 
apo MsbA, Abcb1a, CeAbcb1 and ABCB10, in a conformation made permissible by the 
direct contact of each TMD with both NBDs. ATP may well be bound by the F1-core of 
each NBD but the α-helical subdomain is not engaged (this is the case for ABCB10, and 
also for the maltose importer MalFGK2 in the absence of maltose and its periplasmic 
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binding protein MalE (49)). Drug accesses the inward-open ABCB1 from the inner leaflet 
of the membrane to occupy the cavities lined by Q132 or Q773. The interaction of drug 
with the TMDs triggers conformational change that is transmitted through one or both 
coupling helices (depending on which cavity is occupied and, most likely, on the 
chemistry of the drug/cavity interaction) to bring the two NBDs together. The coupling 
helix most likely flexes the Q-loop to allow the eponymous glutamine to hydrogen bond 
with the γ-phosphate of the ATP that is bound to the F1-core of the same domain (as 
observed in the high resolution structures of soluble bacterial NBDs (22-24)). This 
flexion also rotates the α-helical subdomain forward to hydrogen bond with the second 
ATP bound to the F1-core of the apposed NBD. In the absence of both Q-loop glutamines 
ABCB1 cannot prosecute this conformational change. If only one Q-loop glutamine is 
intact, the transporter presumably locks one ATP into position but not the second. The 
full or partial closure of the NBD:NBD interface (in the wild type and single Q-loop 
mutants, respectively) causes a further conformational change in which the TMD helices 
are re-orientated to close the entrance gate and open the exit gate to release the bound 
drug to the extracellular milieu. The inward-closed conformation is most likely 
autocatalytic (MalK, the isolated NBDs of the maltose importer will hydrolyse ATP 
constitutively in vitro (50)). In ABCB1, hydrolysis of the ATP γ-phosphate likely releases 
the Q-loop and disengages the two NBDs to permit return to the inward-open 
conformation. We speculate that only the ATP locked into position by a hydrogen bond 
to its intradomain Q-loop is hydrolysed. This may explain the reduction by half of the 
verapamil-stimulated ATPase activity of cells expressing the single Q-loop mutants 
without diminution of the Bodipy-verapamil efflux activity. It would also explain the 
pronounced phenotype of the single Walker B mutants, because in this case both ATPs 
would be hydrogen bonded to the two Q-loops and both may therefore need to be 
hydrolysed to disengage the NBDs.   
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Table I. In vitro ATPase data for NBD1-Q475A, NBD2-Q1118A, and wild-
type ABCB1.  
Values shown are the average of at least 4 independent experiments ± S.E.M. * p<0.05, 
*** p<0.001 versus wild-type ABCB1 using Student’s two-tailed t-test. Pa P drug-stimulated 
V Bmax B versus wild-type. 
 
 

















Wild-type 0.746 ± 0.22 1691 ± 228 0.327 ± 0.49 151 ± 54 100 
Q475A 2.37 ± 1.64 162 ± 70*** 0.284 ± 0.19 8.0 ± 1.7* 9.5 




Table II. Cytosensor data for NBD1-Q475A, NBD2-Q1118A, 
Q475A/Q1118A and wild-type ABCB1.  
Values shown are the average of at least 3 independent experiments ± S.E.M. ** p<0.01, 
*** p<0.001 versus wild-type ABCB1 using Student’s two-tailed t-test. ND None 
detected. 
 








Wild-type 0.56 ± 0.03 1.38 ± 0.01 100 23.05 ± 3.44 1.09 ± 0.01 
Q475A 0.91 ± 0.10*** 1.19 ± 0.02*** 50.2 26.54 ± 4.84 0.94 ± 0.02*** 
Q1118A 0.95 ± 0.17** 1.13 ± 0.02*** 35.6 84.81 ± 30.36*** 0.88 ± 0.06*** 







Figure 1. Structural data for ABC exporters.  
(A) A potential bellows-like mechanism of ABC exporters suggested by the structural 
studies. The inward-open conformation of Abcb1a is shown on the left (6). From the 
amino terminus: TMD1, yellow; NBD1, red; TMD2, blue; NBD2, cyan. The inward-
closed conformation of a homology model of human ABCB1 (51) is shown in the centre, 
and on the right rotated 90o on the Y-axis. The inward-closed conformation is based on 
the Sav1866 structure (7) with ATP modelled into the NBDs. The mechanism (15, 52, 53) 
is summarised in four steps (1) drug binds to the inward-open conformation from the inner 
leaflet of the bilayer. (2) This induces conformational change to allow the NBDs to close 
around two ATPs at the NBD:NBD interface. (3) The inward-closed state re-configures 
the drug-binding cavities such that they are now exposed extracellularly and 
simultaneously lowers the affinity for drug, which is released. (4) ATP hydrolysis, loss of 
phosphate (Pi) and ADP, restores the transporter to the inward-open state. (B) The 
verapamil binding cavities. The transmembrane α-helices of the inward-open 
conformation of Abcb1a from above, showing the modelled side chains of residues (red 
sticks) implicated in verapamil binding (54, 55), the prospective verapamil binding 
cavities (dashed red lines), and the conserved glutamines (numbered as for human 
ABCB1) that line the cavities and which when mutated to arginine inhibit binding to the 
adjacent cavity by electrostatic repulsion (spacefill orange and green). (C) Close-up view 
of coupling helix 2 of TMD1 (yellow) formed from the intracellular loop of 
transmembrane α-helices 4 and 5, as it contacts the cleft in NBD2 of the ABCB1 
homology model. The model (viewed from the position of NBD1) shows the Q-loop 
(pink) linking the α-helical subdomain (pale cyan) with the F1-core (cyan) of NBD2. The 
Q-loop also acts as conduit for interaction with the coupling helix. High-resolution 
structure data of bacterial NBDs suggest that the Q-loop glutamine (stick format) of 
ABCB1 will donate a hydrogen bond to the γ-phosphate of the ATP (stick format and 
coloured elementally) bound by the intradomain F1-core. Other TMD α-helices have been 
removed for clarity. (D) Top-down view of the NBD:NBD interface of the ABCB1 
homology model from the position of the TMDs. The F1-core (red) and α-helical 
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(salmon) subdomains of NBD1 are linked by the Q-loop (green). NBD2 is similarly 
shaded in cyan and pale cyan with the Q-loop in pink. The left hand image (cartoon 
format), and the right hand image (surface rendered) show the position of the Q-loops 
lining the base of the clefts that separate the F1-core and α-helical subdomains.  
 
Figure 2. Surface expression, conformational status, and effect on Bodipy-verapamil 
accumulation of mutant and wild-type ABCB1.  
(A) A representative example of a two-wavelength flow cytometry dotplot of HEK293T 
cells transfected with pCIneo-wtABCB1-6His. Cells that express wild-type ABCB1 are 
labelled by the 4E3 anti-ABCB1 antibody and also extrude Bodipy-verapmil. The 
populations are pseudo-coloured blue to red to reflect low to high cell density. (B) A 
representative histogram showing total ABCB1 expression (4E3 binding) on the surface 
of transiently-transfected HEK293T cells. (C) A representative histogram showing the 
effect of the wild-type and mutant ABCB1 on Bodipy-verapamil accumulation. (D) A 
representative histogram showing binding of the conformation-sensitive ABCB1 antibody 
UIC2 to transiently-transfected HEK293T cells. Colour-coding is the same for all 
histograms. 
 
Figure 3. Subcellular localisation of drug accumulation in HEK293T cells expressing wild 
type and mutant ABCB1.  
ABCB1 was detected with non-inhibitory antibody 4E3 (red fluorescence; left hand 
panels), Bodipy-verapamil fluoresces green (centre panels). The right hand panels show 
the merged image. Wild-type ABCB1 is highly active and exports Bodipy-verapamil from 
the cell such that these cells are red but not green (upper panels). Non-expressing cells 
accumulate Bodipy-verapamil intracellularly. The Q475A/Q1118A mutant binds Bodipy-
verapamil in the plasma membrane but cannot efflux it, thus drug accumulates in the 
plasma membrane of cells expressing the double Q-loop mutant ABCB1 and also in 
intracellular compartments (middle panels). In contrast, the catalytically inactive Walker 
B E1201Q mutant is trapped in the inward-closed conformation that has a low affinity for 
drug and these cells accumulate Bodipy-verapamil intracellularly but not in the plasma 
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membrane (lower panels). Fields of view were selected to include a proportion of non-
transfected cells in each panel for comparison. 
 
Figure 4. Purification and ATPase activity of lipid-reconstituted wild-type and mutant 
human ABCB1.  
(A) SDS-polyacrylamide gel stained with colloidal blue, showing total protein from each 
fraction. Lane 1, crude membrane preparation (0.4% of total volume); lane 2, solubilised 
membrane preparation (0.1% of total volume); lane 3, unbound protein in the NiNTA 
resin flow-through (0.1% of total volume); lanes 4-6, washes 1-3 (20mM imidazole; 2.5% 
of total volume); lane 7, wash 4 (30mM imidazole; 2.5% of total volume); lane 8, wash 5 
(35mM imidazole; 2.5% of total volume); lane 9, elution 0 (buffer pH change, 2mM                                 
imidazole; 2.5% of total volume); lanes 10-12, elutions 1-3 (120mM imidazole; 1.5% of 
total volume). (B) ATPase activity of wild-type and mutant ABCB1 in reconstituted 
proteoliposomes, as a function of increasing ATP concentration. Drug-stimulated ATPase 
activity was plotted as a function of ATP concentration using the Michaelis-Menten 
equation. (C) The single Q-loop mutants with a re-scaled y-axis to show the drug-
stimulation of their ATPase activities. 
 
Figure 5. Drug-stimulated ATPase activity of wild-type and mutant ABCB1 measured in 
live cells. 
(A) Extracellular acidification rates (ECARs) of HEK293T cells expressing wild-type 
(red), NBD1-Q475A (purple), or NBD2-Q1118A (orange) ABCB1, and mock-transfected 
cells (blue). Plots are shown as a function of time, with increasing verapamil 
concentration indicated above each experimental peak. (B-E) ECAR data was applied to a 
kinetic model based upon a modified Michaelis-Menten equation, described in the 
Materials and Methods. Representative plots from a single experiment, performed in 
duplicate with error bars indicating standard deviation, are shown using cells expressing 
(B) wild-type, (C) NBD1-Q475A, (D) NBD2-Q1118A, and (E) Q475A/Q1118A ABCB1. 
 
Figure 6. Drug transport activity of wild-type and mutant ABCB1.  
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HEK293T cells expressing ABCB1 were incubated with Bodipy-verapamil for 30min, 
before washing and FACS analysis. Values are calculated as the ratio of FL-1 (drug) 
fluorescence between ABCB1 expressing and non-expressing (untransfected cells) within 
the same sample. Each bar corresponds to the mutation(s) detailed in table below the 
graph. White bars indicate single/double NBD Q-loop mutants; grey, single/double TMD 
mutants; striped bars, double NBD/TMD mutants; black, wild-type; calalytically inactive 
Walker B mutants NBD1-E556Q and NBD2-E1201Q are indicated and serve as negative 
controls. Values shown are the average of at least 5 independent experiments ± S.E.M. † 
cells expressing the Q475A/Q1118A mutant ABCB1 accumulate more Bodipy-verapamil 
than the untransfected cells giving a ratio of less than 1.  * p<0.05, *** p<0.001, ns, not 
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Supplementary Figure 1. The double Q-loop mutant Q475A/Q1118A imports 
Bodipy-verapamil. Dotplot from two-colour flow cytometry experiment (see 
methods and materials in the main text for details), showing the relationship 
between ABCB1 surface expression (4E3 labelling) and Bodipy-verapamil 
accumulation. Each dot represents an individual cell. In the population of cells 
expressing wild-type ABCB1 (red, top left panel) increasing surface labelling 
with 4E3 (and so increasing ABCB1 expression) correlates with decreasing 
accumulation of Bodipy-verapamil (the population to the bottom right of the plot 
are non-transfected cells within the population). Cells expressing the 
catalytically inactive Walker B mutant E1201Q (orange, top centre panel) 
accumulate Bodipy-verapamil to the same level as mock-transfected (or non-
expressing cells within the E1201Q transfection experiment). In contrast, cells 
expressing the double Q-loop mutant Q475A/Q1118A (green, top right panel) 
accumulate more Bodipy verapamil than cells expressing the E1201Q mutant, 
and the level of accumulation goes up with increasing expression of 
Q475A/Q1118A. Direct comparison of the level of Bodipy-verapamil 
accumulation of cells expressing Q475A/Q1118A (green), with mock-transfected 
cells (blue) and cells expressing E1201Q (orange) is given in the overlay plots to 
the bottom left and bottom right, respectively. 
 




































































Supplementary Figure 2. Purified wild-type and mutant ABCB1 was 
reconstituted into liposomes with equal efficiency. Proteoliposomes containing 
(A) wild-type, (B) NBD1-Q475A, (C) NBD2-Q1118A, and (D) Q475A/Q1118A 
ABCB1 were separated using a sucrose density gradient (0-30%). Protein 
content of each fraction was visualised using SDS-PAGE, followed by colloidal 
blue staining (top panels, arrows indicate ABCB1). Distribution of 3H-
phosphatidylcholine between each fraction was determined using liquid 
scintillation counting (bar graphs). Co-fractionation of protein and lipid shows 
















Supplementary Figure 3. TMD mutations Q132R and Q773R do not 
affect the level of ABCB1 surface expression.  
HEK293T cells transiently expressing mutant and wild-type ABCB1 were 
labelled with saturating concentrations of the ABCB1-specific antibody 4E3 to 
label total ABCB1 (see materials and methods in the main text for details). 
 
 
